Role of fluid-phase complement system regulation in the development of hepatitis C virus-associated glomerulonephritis
暂无分享,去创建一个
[1] Chengliang Zhu,et al. Hepatitis B virus inhibits the expression of complement C3 and C4, in vitro and in vivo. , 2018, Oncology letters.
[2] Chengliang Zhu,et al. Hepatitis B virus inhibits the expression of complement C 3 and C 4 , in vitro and in vivo , 2018 .
[3] A. D. den Hollander,et al. A Novel Complotype Combination Associates with Age-Related Macular Degeneration and High Complement Activation Levels in vivo , 2016, Scientific Reports.
[4] C. Schreck,et al. Comparison Between CKD-EPI Creatinine and MDRD Equations to Estimate Glomerular Filtration Rate in Kidney Transplant Patients. , 2016, Transplantation proceedings.
[5] R. Gish,et al. Hepatitis C virus as a systemic disease: reaching beyond the liver , 2015, Hepatology International.
[6] P. Messa,et al. Novel evidence on hepatitis C virus-associated glomerular disease. , 2014, Kidney international.
[7] K. Meyer,et al. Inhibition of C3 Convertase Activity by Hepatitis C Virus as an Additional Lesion in the Regulation of Complement Components , 2014, PloS one.
[8] K. Meyer,et al. Hepatitis C Virus Suppresses C9 Complement Synthesis and Impairs Membrane Attack Complex Function , 2013, Journal of Virology.
[9] F. Fervenza,et al. Membranoproliferative glomerulonephritis--a new look at an old entity. , 2012, The New England journal of medicine.
[10] K. Meyer,et al. Hepatitis C Virus Proteins Inhibit C3 Complement Production , 2011, Journal of Virology.
[11] L. Katz,et al. Allelic Variants of Complement Genes Associated with Dense Deposit Disease , 2011, Journal of the American Society of Nephrology : JASN.
[12] D. Fearon,et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk , 2011, Proceedings of the National Academy of Sciences.
[13] L. Fried,et al. HCV infection and the incidence of CKD. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] K. Meyer,et al. Transcriptional Repression of C4 Complement by Hepatitis C Virus Proteins , 2011, Journal of Virology.
[15] B. Morgan,et al. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. , 2009, Human molecular genetics.
[16] P. Zipfel,et al. Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.
[17] E. Vittinghoff,et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. , 2007, Archives of internal medicine.
[18] M. Walport,et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains , 2007, The Journal of experimental medicine.
[19] M. Matsushita,et al. Cryoprecipitate of patients with cryoglobulinemic glomerulonephritis contains molecules of the lectin complement pathway. , 2001, Clinical immunology.
[20] M. Szklo,et al. Prevalence of Type 2 Diabetes Mellitus among Persons with Hepatitis C Virus Infection in the United States , 2000, Annals of Internal Medicine.
[21] E. Morales,et al. Glomerulonephritis associated with hepatitis C virus infection , 1999 .
[22] C. Alpers,et al. Focal Segmental Glomerular Sclerosis among Patients Infected with Hepatitis C Virus , 1999, Nephron.
[23] Stephen M. Johnson,et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. , 1999, Journal of the American Society of Nephrology : JASN.
[24] V. D’Agati,et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. , 1998, Journal of the American Society of Nephrology : JASN.
[25] K. Chayama,et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. , 1998, Internal medicine.
[26] P. Whelton,et al. Risk of End-stage Renal Disease in Diabetes Mellitus: A Prospective Cohort Study of Men Screened for MRFIT , 1997 .
[27] J. Reichen,et al. Prescribing in liver disease. , 1997, Journal of hepatology.
[28] C. Alpers,et al. Hepatitis C virus-associated glomerulonephritis. Effect of α-interferon therapy , 1994 .
[29] K. Whaley,et al. Interferon-induced transcriptional and post-transcriptional modulation of factor H and C4 binding-protein synthesis in human monocytes. , 1990, The Biochemical journal.
[30] K. Whaley,et al. Regulation of C1-inhibitor synthesis by interferons and other agents. , 1989, Behring Institute Mitteilungen.
[31] J. Weiler,et al. Steroids inhibit activation of the alternative-amplification pathway of complement , 1983, Infection and immunity.